Vaxzevria (AstraZeneca) as a Covid-19 Vaccination


Authors : Varsini S.R

Volume/Issue : Volume 7 - 2022, Issue 6 - June

Google Scholar : https://bit.ly/3IIfn9N

Scribd : https://bit.ly/3uCjFex

DOI : https://doi.org/10.5281/zenodo.6812559

Abstract : The vaxzevria is a vaccine for preventing covid19 caused by SARS-CoV-2 virus in people from the age of 18 years and older. Also known as Astra-Zeneca or (ChAdOx1 S [recombinant]). The vaccine is 63% effective in an ongoing, large-scale clinical trial. The vaccine has been modified to induce either of mRNA COVID-19 vaccines (Pfizer or Moderna). They can be used as a second dose in cases where Astra Zeneca was given as the first dose. Though the vaccine has been approved in nearly 138 countries, a total of 184,679 cases of side effects were reported. The vaccine has reported to prevent over 50 million COVID-19 cases. The vaccine is taken as 2 doses plus a booster dose of injections.

Keywords : Astra-Zeneca; AZD1222; Covid -19; Delta Variant; Side Effects; TTS

The vaxzevria is a vaccine for preventing covid19 caused by SARS-CoV-2 virus in people from the age of 18 years and older. Also known as Astra-Zeneca or (ChAdOx1 S [recombinant]). The vaccine is 63% effective in an ongoing, large-scale clinical trial. The vaccine has been modified to induce either of mRNA COVID-19 vaccines (Pfizer or Moderna). They can be used as a second dose in cases where Astra Zeneca was given as the first dose. Though the vaccine has been approved in nearly 138 countries, a total of 184,679 cases of side effects were reported. The vaccine has reported to prevent over 50 million COVID-19 cases. The vaccine is taken as 2 doses plus a booster dose of injections.

Keywords : Astra-Zeneca; AZD1222; Covid -19; Delta Variant; Side Effects; TTS

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe